| Literature DB >> 29782483 |
Yanli Deng1,2, Xuefeng Han3, Shaoxun Tang3, Chengjian Li4, Wenjun Xiao5, Zhiliang Tan3.
Abstract
BACKGROUND The cortex of Magnolia officinalis has long been used as an element of traditional Chinese medicine for the treatment of anxiety, chronic bronchitis, and gastrointestinal dysfunction. This study aimed to elucidate the underlying mechanism of its functional ingredients (magnolol and honokiol) in modifying the secretion and absorption homeostasis and protecting mucosal integrity in an Enterotoxigenic Escherichia coli (ETEC)-induced diarrhea mouse model. MATERIAL AND METHODS This study established a diarrhea mouse model infected by ETEC at a dosage of 0.02 ml/g live body weight (BW) in vivo. Magnolol or honokiol was followed by an intraperitoneal administration at dosages of 100, 300, and 500 mg/kg BW according to a 3×3 factorial arrangement. The useful biomarkers for evaluating the integrity of intestinal tract and histologic injury were analyzed and morphological development (including villus height, crypt depth, and ratio of villus height to crypt depth) and the expressions of inflammatory cytokines were determined by real-time PCR. RESULTS The results showed that magnolol and honokiol (500 mg/kg BW) reduced the concentrations of NO, DAO, and DLA, and iNOS activity, and the mRNA expressions of the interferon gamma (IFN-γ) and interleukin 10 (IL-10), and inhibited intestinal epithelial cell apoptosis. Magnolol and honokiol (300 mg/kg BW) elongated the villus height and crypt depth and decreased the number of goblet cells and the ratio of villus height to crypt depth. CONCLUSIONS The current results indicate that magnolol and honokiol enhance the intestinal anti-inflammatory capacities, elongate the villus height and crypt depth, and reduce goblet cell numbers to inhibit the intestinal epithelium apoptosis and effectively protect the intestinal mucosa. These results show that magnolol and honokiol protect the intestinal mucosal integrity and regulate gastrointestinal dysfunction.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29782483 PMCID: PMC5990993 DOI: 10.12659/MSM.910350
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Experimental treatments.
| Groups | Group description | Treatments design |
|---|---|---|
| Group 1 | Normal control group (NC) | All mice were treated with sterile water |
| Group 2 | Diarrhea model control group (MC) | All mice were infected by ETEC |
| Group 3 | Positive drug control group (PC) | All mice were infected by ETEC, and then were orally gavaged with loperamide hydrochloride 3 mg/kg BW |
| Group 4 | Plant extract group 1 | All mice were infected by ETEC, and then were administered the magnolol 100 mg/kg BW and honokiol 100 mg/kg BW |
| Group 5 | Plant extract group 2 | All mice were infected by ETEC, and then were administered the magnolol 100 mg/kg BW and honokiol 300 mg/kg BW |
| Group 6 | Plant extract group 3 | All mice were infected by ETEC, and then were administered the magnolol 100 mg/kg BW and honokiol 500 mg/kg BW |
| Group 7 | Plant extract group 4 | All mice were infected by ETEC, and then were administered the magnolol 300 mg/kg BW and honokiol 100 mg/kg BW |
| Group 8 | Plant extract group 5 | All mice were infected by ETEC, and then were administered the magnolol 300 mg/kg BW and honokiol 300 mg/kg BW |
| Group 9 | Plant extract group 6 | All mice were infected by ETEC, and then were administered the magnolol 300 mg/kg BW and honokiol 500 mg/kg BW |
| Group 10 | Plant extract group 7 | All mice were infected by ETEC, and then were administered the magnolol 500 mg/kg BW and honokiol 100 mg/kg BW |
| Group 11 | Plant extract group 8 | All mice were infected by ETEC, and then were administered the magnolol 500 mg/kg BW and honokiol 300 mg/kg BW |
| Group 12 | Plant extract group 9 | All mice were infected by ETEC, and then were administered the magnolol 500 mg/kg BW and honokiol 500 mg/kg BW |
Sequences of primers and PCR products size of real-time quantitative PCR.
| Gene | GenBank accession | Forward primer (5′-3′) | Reverse primer (5′-3′) | Product size (bp) |
|---|---|---|---|---|
| β-actin | NM_007393 | AGAGGGAAATCGTGCGTGAC | CAATAGTGATGACCTGGCCGT | 139 |
| TNF-α | NM_013693 | CATCTTCTCAAAATTCGAGTGACAA | TGGGAGTAGACAAGGTACAACCC | 175 |
| IFN-γ | NM_008337 | TCAAGTGGCATAGATGTGGAAGAA | TGGCTCTGCAGGATTTTCATG | 92 |
| IL-6 | NM_031168 | GAGGATACCACTCCCAACAGACC | AAGTGCATCATCGTTGTTCATACA | 141 |
| IL-10 | NM_010548 | GGTTGCCAAGCCTTATCGGA | ACCTGC CCACTGCCTTGCT | 190 |
| iNOS | NM_010927 | CAGCTGGGCTGTACAAACCTT | ATTGGAAGTGAAGCGTTTCG | 94 |
TNF-α – tumor necrosis factor alpha; IFN-γ – interferon gamma; IL-6 – interleukin 6; IL-10 – interleukin 10; iNOS – inducible nitric oxide synthase.
Effects of oral magnolol and honokiol administration on NO and iNOS concentration of ileal tissue, serum DAO, GLU, and LAD content in mice (n=10).
| Item | Treatment | SEM | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NC | MC | PC | M | H | ||||||||||
| 100 | 300 | 500 | 100 | 300 | 500 | M | H | M×H | ||||||
| Ileum | NO μmol/g prot | 3.11c | 11.28a | 3.79c | 5.75bc | 5.73bc | 5.01bc | 9.20ab | 7.67abc | 5.32bc | 2.329 | 0.661 | 0.041 | <0.001 |
| iNOS U/mg prot | 0.73abcd | 0.92a | 0.89a | 0.75abc | 0.54cde | 0.39e | 0.81ab | 0.59bcde | 0.49de | 0.109 | <0.010 | 0.003 | 0.012 | |
| Serum | DAO U/L | 3.73abc | 4.32ab | 4.54a | 3.73abc | 3.41bc | 3.18c | 4.21ab | 3.60bc | 3.64abc | 0.396 | 0.046 | 0.099 | 0.996 |
| GLU mmol/L | 5.04b | 5.75ab | 5.93ab | 6.07ab | 6.42ab | 5.66ab | 4.89b | 7.20a | 6.08ab | 0.924 | 0.556 | 0.006 | 0.008 | |
| DLA mg/dL | 40.95b | 77.80a | 36.54bc | 34.06bc | 29.05c | 35.05bc | 30.51c | 32.81c | 34.42bc | 3.526 | 0.038 | 0.139 | <0.001 | |
NO – nitric oxide; iNOS – induced nitric oxide synthase; DAO – diamine oxidase; GLU – glucose; DLA – lactic acid.
In a row, the mean values with different letters (a–e) differ (P<0.05).
NC – normal control; MC – diarrhea model control; PC – positive drug control; M – magnolol administration at the doses of 100, 300, and 500 mg/kg BW; H – Honokiol administration at the doses of 100, 300, and 500 mg/kg BW.
Standard error of least squares means.
Effects of oral magnolol and honokiol administration on the mRNA expression of nitric oxide synthases and inflammatory cytokines in mice (n=10).
| Item | Treatment | SEM | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NC | MC | PC | M | H | |||||||||
| 100 | 300 | 500 | 100 | 300 | 500 | M | H | M × H | |||||
| iNOS | 1.00b | 1.88ab | 2.60a | 1.64b | 1.37b | 1.01b | 1.64b | 1.60b | 1.25b | 0.443 | 0.004 | 0.214 | <0.001 |
| TNF-α | 1.00 | 1.74 | 1.54 | 1.43 | 1.18 | 1.09 | 1.27 | 0.89 | 1.06 | 0.386 | 0.418 | 0.049 | 0.004 |
| IFN-γ | 1.00c | 2.08a | 1.53abc | 1.99ab | 0.89c | 0.78c | 1.51abc | 1.21bc | 1.06c | 0.366 | <0.001 | 0.081 | <0.001 |
| IL-6 | 1.00ab | 1.29ab | 0.60b | 1.38a | 0.93ab | 0.82ab | 1.26ab | 1.08ab | 0.78ab | 0.310 | 0.018 | 0.071 | 0.001 |
| IL-10 | 1.00d | 4.04a | 2.63abc | 3.12ab | 2.21bcd | 0.74d | 2.73ab | 2.10bcd | 1.17cd | 0.691 | <0.001 | <0.001 | <0.001 |
iNOS – nitric oxide synthases; TNF-α – tumor necrosis factor alpha; IFN-γ – interferon gamma; IL-6 – interleukin 6; IL-10 – interleukin 10.
In a row, the mean values with different letters (a–d) differ (P<0.05).
NC – normal control; MC – diarrhea model control; PC – positive drug control; M – magnolol administration at the doses of 100, 300, and 500 mg/kg BW; H – Honokiol administration at the doses of 100, 300, and 500 mg/kg BW.
Standard error of least squares means.
Figure 1Effects of magnolol and honokiol on ETEC-induced changes in histopathology of the ileal tissue in mice of different experimental groups (n=5, ×250). The lengths of 30 villi were measured by the distance in μm from the crypt neck to the villus tip, the depths of 30 crypts were determined, and the goblet cells in each 30 oriented villi were counted. The mice were first infected by ETEC suspensions and then treated by loperamide hydrochloride or magnolol and honokiol. (A) Shows the normal appearance of normal control mice. (B) Shows the appearance of ETEC-induced mice. (C) Shows the appearance of loperamide hydrochloride-treated ETEC-induced mice. (D–L) Shows the appearance of 100 mg magnolol/kg BW (M100) ×100 mg honokiol/kg BW (H100) administration, M100×H300, M100×H500, M300×H100, M300×H300, M300×H500, M500×H100, M500×H300, and M500×H500 treated ETEC-induced mice.
Effects of oral magnolol and honokiol administration on the morphology of ileal in mice (n=5).
| Item | Treatment | SEM | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NC | MC | PC | M | H | |||||||||
| 100 | 300 | 500 | 100 | 300 | 500 | M | H | M × H | |||||
| VH, μm | 344.06a | 229.98bc | 195.56c | 271.03abc | 288.67ab | 274.37abc | 284.51ab | 316.27ab | 233.28bc | 37.132 | 0.830 | 0.033 | 0.381 |
| CD, μm | 174.02a | 108.24b | 121.62ab | 159.09ab | 167.89a | 155.63ab | 173.59a | 170.17a | 138.85ab | 24.638 | 0.825 | 0.184 | 0.185 |
| GC | 24.40a | 22.40a | 12.20b | 5.80c | 4.63c | 6.53bc | 8.07bc | 3.83c | 5.07c | 2.629 | 0.633 | 0.107 | 0.124 |
| VH/CD | 2.00ab | 2.14a | 1.69c | 1.72c | 1.75bc | 1.81bc | 1.68c | 1.89abc | 1.71c | 0.119 | 0.598 | 0.038 | 0.116 |
VH – Villus height; CD – Crypt depth; GC – Goblet cell; VH/CD – ratio of Villus height to Crypt depth;
In a row, the mean values with different letters (a–c) differ (P<0.05).
NC – normal control; MC – diarrhea model control; PC – positive drug control; M – magnolol administration at the doses of 100, 300, and 500 mg/kg BW; H – Honokiol administration at the doses of 100, 300, and 500 mg/kg BW.
Standard error of least squares means.
Figure 2The apoptosis appearance of ETEC-induced ileum tissues treated by magnolol and honokiol in mice of different experimental groups (n=5, ×400). DNA fragmentation was examined by terminal deoxynucleotidyl transferase mediated dUTP nick-end labeling staining. (A) Shows the apoptosis appearance of the normal control mice. (B) Shows the apoptosis appearance of ETEC-induced mice. (C) Shows the apoptosis appearance of loperamide hydrochloride-treated ETEC-induced mice. (D–L) Shows the apoptosis appearance of magnolol and honokiol administration at 100 mg/kg BW (M100) ×100 mg/kg BW (H100), M100×H300, M100×H500, M300×H100, M300×H300, M300×H500, M500×H100, M500×H300, and M500×H500 treated ETEC-induced mice.
Effects of oral magnolol and honokiol administration on the average optical density of ileal epithelium in ETEC-induced diarrhea mice (TUNEL assay, n=5).
| Item | Treatment | SEM | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NC | MC | PC | M | H | |||||||||
| 100 | 300 | 500 | 100 | 300 | 500 | M | H | M × H | |||||
| AID | 0.17ab | 0.20a | 0.12b | 0.20ab | 0.16ab | 0.13ab | 0.18ab | 0.15ab | 0.16ab | 0.032 | 0.046 | 0.500 | 0.332 |
AID – average optical density;
In a row, the mean values with different letters (a–b) differ significantly (P<0.05).
NC – normal control; MC – diarrhea model control; PC – positive drug control; M – magnolol administration at the doses of 100, 300, and 500 mg/kg BW; H – Honokiol administration at the doses of 100, 300, and 500 mg/kg BW;
Standard error of least squares means.